ArticleJournal of managed care & specialty pharmacy2026
Prevalence of renal and bone risk factors and nucleos(t)ide analogue treatment among patients with chronic hepatitis B in the United States.
Article in Journal of managed care & specialty pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic hepatitis B (CHB) can lead to serious health complications. Patients with CHB often have a higher burden of extrahepatic comorbidities such as chronic kidney disease (CKD) and osteopenia/osteoporosis (OP) compared with the general population. Understanding the burden of these comorbidities in those with CHB may facilitate the development of strategies to better support patients and guide treatment decisions.
objectiveTo evaluate demographic characteristics and prevalence of CKD, OP, and established risk factors for CKD and OP in patients with a confirmed diagnosis of CHB and assess prevalence of nucleos(t)ide analogue (NA) use in the United States.
methodsThis study evaluated retrospective claims data from Optum's deidentified Clinformatics® Data Mart database between January 1, 2016, and March 31, 2025. Commercially and Medicare-insured adults (aged ≥18 years) with a confirmed diagnosis of CHB (≥1 inpatient or ≥2 outpatient diagnostic codes ≥30 days apart) who met continuous enrollment criteria and had no evidence of HIV infection were included. Descriptive analyses were carried out to estimate the prevalence of CKD, OP, related established risk factors, and NA treatment experience.
resultsA total of 19,176 patients with CHB meeting eligibility were identified; 73% were older than 50 years, and 53% were male. Twenty-seven percent received NA treatment during the observation period: tenofovir disoproxil fumarate was most commonly used (14%), followed by entecavir (12%) and tenofovir alafenamide (7%). More than one-quarter (30%) of patients had CKD, including 9% with stage 4 or 5 CKD. Among patients with CHB, renal risk factors were prevalent, with 80% and 27%, respectively, having risk factors for CKD related to a comorbidity or medication use. More than one-quarter (29%) of the patients had a diagnosis of OP. Risk factors for OP were also prevalent, with 72% and 60% of patients, respectively, having a risk factor for OP-driven comorbidities or medication use. The overall prevalence of renal- and bone-related comorbidities and risk factors was similar among patients treated with NAs.
conclusionsThis study demonstrates the high burden of comorbidities among patients with CHB, with established risk factors for CKD and OP present among most individuals. Although NAs are the mainstay therapy for CHB, different safety considerations exist for each therapy, and this analysis found that fewer than one-third of patients had a history of NA use. These findings highlight the importance of considering the renal and bone safety profiles of CHB treatment options to help mitigate comorbidities and prevent complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.